Along with the social construction of population aging, the incidence of CNS disorders, including Alzheimer disease (AD), Parkinson disease (PD), and depression, is continuously increasing . However, the number of approved drugs targeting these diseases remains limited, partially attributed to the blood-brain barrier (BBB) that prevents the access of drug molecules into the CNS . Consequently, discovery and development of novel and effective drugs for the treatment of human CNS disorders remains a crucial responsibility in the field of pharmaceutical sciences .